Human papilomavirus detection in cervical cancer prevention;Detección de virus papiloma humano en la prevención del cáncer cérvico-uterino

Medicina (Argentina)

Volumn 73, Issue 6, 2013, Pages 585-596

  Picconi, María Alejandra ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

Cervical cancer; Cervical screening; Clinical validation; Human papillomavirus (HPV); Screening techniques

Indexed keywords

CERVICAL CANCER; CERVICAL SCREENING; CLINICAL VALIDATION; HUMAN PAPILLOMAVIRUS (HPV); SCREENING TECHNIQUES;

ALPHAPAPILLOMAVIRUS; ARGENTINA; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; ONCOGENIC VIRUSES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84893951283     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-9.
2. zur Hausen H. Papillomavirus infection-a major cause of human cancers. Biochim Biophys Acta 1996; 1288, F55-78.
3. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 Suppl 5: F55-70.
4. Crow JM. HPV: The global burden. Nature 2012; 488: S2-3.
5. Ministerio de Salud de la Nación, Instituto Nacional del Cáncer, Dirección de Estadísticas e Información de Salud. Lineamientos Técnicos de la Vacunación contra VPH, 2011. En: http://www.msal.gov.ar/images/stories/epidemiologia/inmunizaciones/equipos-de-salud/lineamientos-tecnicos-vph-2011.pdf; consultado 05/03/2013.
6. Centers for Diseases Control and Prevention. HPV and Cancer. En: http://www.cdc.gov/hpv/cancer.html; consultado 27/03/2013.
7. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010; 10: 7-17.
8. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5, Suppl 1): 3-8.
9. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
10. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
11. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
12. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
13. Matos E, Loria D, Amestoy GM, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003; 30: 593-9.
14. Deluca GD, Basiletti J, González JV, Díaz Vásquez N, Lucero RH, Picconi MA. Human papilloma virus risk factors for infection and genotype distribution in aboriginal women from Northern Argentina. Medicina (B Aires) 2012; 72: 461-6.
15. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64.
16. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5.
17. Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS One 2011; 6: e25493.
18. Picconi MA, Alonio LV, García Carrancá A, et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina (B Aires) 2000; 60: 889-94.
19. Quint W, Jenkins D, Molijn A, et al. One virus, one lesion--individual components of CIN lesions contain a specific HPV type. J Pathol 2012; 227: 62-71.
20. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005; 353: 2101-4.
21. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995; 64: 1-378.
23. McLaughlin-Drubin ME, Meyers J, Munger K. Cancer associated human papillomaviruses. Curr Opin Virol 2012; 2: 459-66.
24. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
25. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers 2007; 23: 273-81.
26. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
27. Snijders PJF, Heideman DAM, Meijer CJLM. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010; 118: 520-8.
28. Chan PK, Picconi MA, Cheung TH, Giovannelli L, Park JS. Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci 2012; 49: 117-36.
29. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 2012; 30 Suppl 5: F100-6.
30. Eklund C, Zhou T, Dillner J. WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010; 48: 4147-55.
31. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010; 134: 193-9.
32. Stoler MH, Castle PE, Solomon D, Schiffman M. American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated tests. Am J Clin Pathol 2007; 127: 335-7.
33. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009; 125: 2489-96.
34. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (Suppl 3): S78-89.
35. Cuschieri K. Human papillomavirus testing: the challenges of picking the right tools for the job. Exp Rev Obstet Gynecol 2011; 6: 643-53.
36. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648-59.
37. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol 2009; 45 (Suppl. 1): S3-12.
38. Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441-50.
39. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 (Suppl 10): K29-41.
40. Cuzick J, Bergeron C, von Knebel Doeberitz, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012; 30(S5): F107-16.
41. Gupta N, Srinivasan R, Rajwanshi A. Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 2010; 38: 618-23.
42. Ministerio de Salud de la Nación, Instituto Nacional del Cáncer, Programa Nacional de Prevención de Cáncer Cérvico-Uterino. Guía para la utilización de la prueba de VPH como método de tamizaje primario en la Argentina. Diciembre 2011.
43. Schweizer J, Lu PS, Mahoney CW, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010; 48: 4646-8.
44. Poljak M, Kocjan BJ. Commercially available tests for multiplex detection of alpha human papillomaviruses. Exp Rev Anti Infect Ther 2010; 8: 1139-62.
45. Arbyn M, Dillner J, Schenck U, et al. Methods for screening and diagnosis. In: Arbyn M, Anttila A, Jordan J, et al., editors. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd edition Luxembourg: Office for Official Publications of the European Communities; 2008. p 69-152.
46. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 Suppl 5: F88-99.
47. Kreimer AR, Guido RS, Solomon D, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006; 15: 908-14.
48. Einstein MH, Martens MG, Garcia FA, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010; 118: 116-22.
49. Belinson JL, Wu R, Belinson SE, et al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol 2011; 135: 790-5.
50. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-36.
51. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
52. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135: 468-75.
53. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
54. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV16 and HPV18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011; 136: 578-86.
55. Heideman, DAM, Hesselink AT, Berkhof J, et al. Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes. J Clin Microbiol 2011, 49: 3983-5.
56. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J; Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208: 184. e1-184. e11.
57. Cuzick J, Ambroisine L, Cadman L, et al. Performanceof the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010; 82: 1186-91.
58. Huang S, Erickson B, Tang N, et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol 2009; 45 (Suppl. 1): S19-23.
59. Poljak M, Ostrbenk A, Seme K, et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011; 49: 1721-9.
60. Carozzi FM, Burroni E, Bisanzi S, et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 test in a screening setting. J Clin Microbiol 2011; 49: 1446-51.
61. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17: 2536-45.
62. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011; 120: 430-8.
63. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC. Efficiency of the APTIMA HPV Test for detection of HPV RNA and DNA targets. J Clin Virol 2009; 45 (Suppl. 1): S49-54.
64. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011; 129: 691-701.
65. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Smith JS. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study). Gynecol Oncol 2012; 125: 175-80.
66. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
67. Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid-sequence based amplification test for HPV mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol 2010; 48: 2524-9.
68. Hovland S, Arbyn M, Lie AK, et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. Br J Cancer 2010; 102: 957-65.
69. Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA test in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010; 48: 2779-85.
70. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-42.
71. Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA test as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011; 49: 2643-50.
72. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. Triage of women with low-grade cervical lesions-HPV mRNA testing versus repeat cytology. PLoS One 2011; 6: e24083.
73. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 2011; 6: e26022.
74. Tabrizi SN. Quality assessment for human papillomavirus testing. Sex Health 2010; 7: 335-7.
75. WHO_HPV_LabNet. En: www.who.int/biologicals/areas/humanpapillomavirus/WHO_HPV_LabNet/en/index.html; consultado 05/03/2013.
76. Fagan EJ, Moore C, Jenkins C, Rossouw A, Cubie HA, James VL. External quality assessment for molecular detection of human papillomaviruses. J Clin Virol 2010; 48: 251-4.
77. st Edition Geneva: World Health Organization; 2009. En: http://www.who.int/immunization/documents/en/; consultado 01/05/12.